– Achieved Third Quarter 2023 Total Revenue of
$36.0 Million and U.S. XPOVIO®
(selinexor) Net Product Revenue of $30.2
Million –
– Maintains Full Year 2023 Total Revenue
Guidance of $145 Million to
$160 Million, Including U.S. XPOVIO
Net Product Revenue Guidance of $110
Million to $125 Million
–
– Strong SVR and TSS Durability Observed
from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK
Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with No SVR or TSS
Progressions Observed 1 –
– Announced Clinical Trial Collaboration with
Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480,
Mezigdomide in Combination with Selinexor in Patients with R/R
Multiple Myeloma Progressing After T-cell Immunotherapies –
– Conference Call Scheduled for Today at
8:00 a.m. ET –
NEWTON,
Mass., Nov. 2, 2023 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today reported financial
results for the quarter ended September 30,
2023, and highlighted select corporate milestones and
progress on its key clinical development programs.
"We are strongly positioned for our next stage of growth driven
by our focused and rapidly advancing late-stage pipeline with
evolving data including impressive durability data observed with
selinexor 60mg in combination with ruxolitinib in patients with
myelofibrosis as well as the substantial progression-free survival
observed in patients with TP53 wild-type endometrial
cancer," said Richard Paulson,
President and Chief Executive Officer of Karyopharm. "Our
commercial organization continues to perform with resilience amidst
an increasingly competitive multiple myeloma landscape, focusing on
fueling growth in the community and expanding use of selinexor in
the earlier lines."
Third Quarter 2023 and Recent Highlights
XPOVIO Commercial Performance
- Achieved U.S. net product revenue of $30.2 million for the third quarter of 2023,
compared to $32.0 million U.S. net
product revenue in the third quarter of 2022.
- Net XPOVIO revenue continued to be adversely impacted year over
year by increased utilization of the KaryForward Patient Assistance
Program (PAP), resulting from multiple myeloma foundation
closures2 and higher gross-to-net driven by increased
340B discounts and Medicaid rebates,
as compared to the third quarter of 2022. During the third quarter
of 2023, new patient starts within the PAP normalized, although the
impact from refills remained.
- Total demand for XPOVIO was adversely impacted by 3% year over
year, largely due to increasing competitive pressures seen in the
later lines in the academic setting.
- Continued shift in earlier lines with more than 60%3
of all XPOVIO new starts in the second to fourth line, representing
approximately 20% year over year growth.
- The National Comprehensive Cancer Network® (NCCN) Clinical
Practice Guidelines elevated XPOVIO in combination with bortezomib
(Velcade®) and dexamethasone (XVd) to a preferred and category 1
regimen for lenalidomide refractory patients with relapsed or
refractory multiple myeloma who have received one-to-three prior
lines of therapy in the September
2023 Clinical Practice Guidelines in Oncology.
R&D Highlights
Myelofibrosis
- Data from the Phase 1 study evaluating the safety and efficacy
of once-weekly selinexor in combination with ruxolitinib in
patients with JAKi-naïve myelofibrosis (NCT04562389) on durability
of response is being presented today at the 15th
International Congress on Myeloproliferative
Neoplasms. As of the August 1,
2023 data cut-off date, all patients treated with 60mg
selinexor and who achieved ≥35% reduction in spleen volume (SVR35)
at week 24 (n=11), continued to remain in radiographic
response1. In addition, all of the 7 patients who
achieved TSS50 at Week 24 remained in response as of the data
cut-off1. The maximum duration of follow-up was 78 weeks
with a median duration of 32 weeks for SVR35 durability, and a
maximum duration of follow-up was 64 weeks with a median duration
of 51 weeks for TSS50 durability.
Endometrial Cancer
- The Phase 3 SIENDO study (NCT03555422) manuscript was published
in the Journal of Clinical Oncology.
- Long term exploratory subgroup analysis of the pre-specified
subgroup of patients with advanced or recurrent TP53
wild-type endometrial cancer from the SIENDO study was presented as
an encore oral presentation at the 24th European Gynaecological
Oncology Congress (ESGO) in September.
- Presented pre-clinical data from patient derived cancer models
at the 2023 AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics that suggest TP53 wild-type
status may predict sensitivity to exportin 1 (XPO1) inhibitors
selinexor and eltanexor in multiple cancer types, including
endometrial, ovarian, kidney, liver, esophageal, lung, pancreatic
and bladder, and that sensitivity was similar for both eltanexor
and selinexor. These data support the importance of TP53
wild-type status with XPO1 inhibition in endometrial cancer.
Multiple Myeloma
- The Company entered into a clinical trial collaboration and
supply agreement with Bristol Myers Squibb (BMS) to evaluate BMS'
proprietary investigational cereblon E3 ligase modulator (CELMoD™)
agent mezigdomide in combination with selinexor in patients with
relapsed/refractory multiple myeloma progressing after T-cell
immunotherapies. This trial will evaluate mezigdomide in
combination with selinexor doses of either 40mg or 60mg plus
dexamethasone in patients who have prior exposure to
immunomodulatory drug agent, proteasome inhibitors, and anti-CD38
monoclonal antibody treatment. All patients must have received at
least two prior lines of therapy, and either have progressed after
or are not eligible to receive CAR-T or bispecific antibody
treatment. Under the terms of the agreement with BMS, Karyopharm
will sponsor the trial as a new arm of its Phase 1b/2 STOMP trial and BMS will supply the study's
clinical drug mezigdomide.
Third Quarter 2023 Financial Results
Total Revenues: Total revenue for the third quarter
of 2023 was $36.0 million, compared
to $36.1 million for the third
quarter of 2022.
Net product revenue: Net product revenue for the
third quarter of 2023 was $30.2
million, compared to $32.0
million for the third quarter of 2022.
License and other revenue: License and other revenue for
the third quarter of 2023 was $5.8
million, compared to $4.1
million for the third quarter of 2022. The increase was
primarily due to an increase in revenue for the reimbursement of
development-related expenses from the Menarini Group.
Cost of sales: Cost of sales for the third quarter
of 2023 was $0.9 million, compared to
$1.0 million for the third quarter of
2022. Cost of sales reflects the costs of XPOVIO units sold and
third-party royalties on net product revenue.
Research and development (R&D) expenses: R&D
expenses for the third quarter of 2023 were $35.6 million, compared to $31.4 million for the third quarter of 2022. The
increase was primarily due to higher clinical trial costs related
to the advancement of our three pivotal Phase 3 programs.
Selling, general and administrative (SG&A)
expenses: SG&A expenses for the third quarter of 2023
were $30.8 million, compared to
$34.6 million for the third quarter
of 2022. The decrease was primarily due to a decrease in
consulting, professional and other costs as a result of more
focused commercial-related activities due to lower headcount.
Interest income: Interest income for the third
quarter of 2023 was $2.8 million,
compared to $0.7 million for the
third quarter of 2022, due to higher average interest rates on
investments.
Interest expense: Interest expense for the third
quarters of both 2023 and 2022 was $6.1
million.
Net loss: Karyopharm reported a net loss of
$34.5 million, or $0.30 per share, for the third quarter of 2023,
compared to a net loss of $36.3
million, or $0.45 per share,
for the third quarter of 2022.
Cash position: Cash, cash equivalents, restricted
cash and investments as of September 30,
2023 totaled $209.2 million,
compared to $279.7 million as of
December 31, 2022.
2023 Financial Outlook
Based on its current operating plans, Karyopharm reiterates its
guidance for full year 2023 as follows:
- Total revenue expected to be in the range of $145 million to $160
million. Total revenue consists of U.S. XPOVIO net product
revenue and license, royalty and milestone revenue earned from
partners.
- U.S. XPOVIO net product revenue expected to be in the range of
$110 million to $125 million.
- Non-GAAP R&D and SG&A expenses*, which exclude
stock-based compensation expense, expected to be in the range of
$240 million to $255 million.
- The Company continues to expect that its existing cash, cash
equivalents and investments, and the revenue it expects to generate
from XPOVIO net product sales, as well as revenue generated from
its license agreements, will be sufficient to fund its planned
operations into late 2025.
* Karyopharm has not reconciled the full year 2023 outlook for
non-GAAP R&D and SG&A expenses to full year 2023 outlook
for GAAP R&D and SG&A expenses because Karyopharm cannot
reliably predict without unreasonable efforts the timing or amount
of the factors that substantially contribute to the projection of
stock compensation expense, which is excluded from the full year
2023 outlook for non-GAAP R&D and SG&A expenses.
Non-GAAP Financial Information
Karyopharm uses a non-GAAP financial measure, non-GAAP R&D
and SG&A expenses, to provide operating expense guidance.
Non-GAAP R&D and SG&A expenses exclude stock-based
compensation expense. Karyopharm believes this non-GAAP financial
measure is useful to investors because it provides greater
transparency regarding Karyopharm's operating performance as it
excludes non-cash stock compensation expense. This non-GAAP
financial measure should not be considered a substitute or an
alternative to GAAP R&D and SG&A expenses and should not be
considered a measure of Karyopharm's liquidity. Instead, non-GAAP
R&D and SG&A expenses should only be used to supplement an
understanding of Karyopharm's operating results as reported under
GAAP.
Conference Call Information
Karyopharm will host a conference call today, November 2, 2023, at 8:00
a.m. Eastern Time, to discuss the third quarter 2023
financial results and financial outlook for 2023 and to provide
other business highlights. To access the conference call, please
dial (888) 349-0102 (local) or (412) 902-4299 (international) at
least 10 minutes prior to the start time and ask to be joined into
the Karyopharm Therapeutics call. A live audio webcast of the call,
along with accompanying slides, will be available under "Events
& Presentations" in the Investor section of the Company's
website,
http://investors.karyopharm.com/events-presentations. An
archived webcast will be available on the Company's website
approximately two hours after the event.
About XPOVIO® (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor and
the first of Karyopharm's Selective Inhibitor of Nuclear Export
(SINE) compounds to be approved for the treatment of cancer. XPOVIO
functions by selectively binding to and inhibiting the nuclear
export protein XPO1. XPOVIO is approved in the U.S. and marketed by
Karyopharm in multiple oncology indications, including: (i) in
combination with VELCADE® (bortezomib) and dexamethasone (XVd) in
patients with multiple myeloma after at least one prior therapy;
(ii) in combination with dexamethasone in patients with heavily
pre-treated multiple myeloma; and (iii) in patients with diffuse
large B-cell lymphoma (DLBCL), including DLBCL arising from
follicular lymphoma, after at least two lines of systemic therapy.
XPOVIO (also known as NEXPOVIO® in certain countries) has received
regulatory approvals in a growing number of ex-U.S. territories and
countries, including Europe, the
United Kingdom, China, South
Korea and Israel, and is
marketed in those areas by Karyopharm's global partners. Selinexor
is also being investigated in several other mid- and late-stage
clinical trials across multiple high unmet need cancer indications,
including in endometrial cancer and myelofibrosis.
For more information about Karyopharm's products or clinical
trials, please contact the Medical Information department at:
Tel: +1 (888) 209-9326; Email:
medicalinformation@karyopharm.com
XPOVIO® (selinexor) is a prescription medicine
approved:
- In combination with bortezomib and dexamethasone for the
treatment of adult patients with multiple myeloma who have received
at least one prior therapy (XVd).
- In combination with dexamethasone for the treatment of adult
patients with relapsed or refractory multiple myeloma who have
received at least four prior therapies and whose disease is
refractory to at least two proteasome inhibitors, at least two
immunomodulatory agents, and an anti–CD38 monoclonal antibody
(Xd).
- For the treatment of adult patients with relapsed or refractory
diffuse large B–cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from follicular lymphoma, after at least
two lines of systemic therapy. This indication is approved under
accelerated approval based on response rate. Continued approval for
this indication may be contingent upon verification and description
of clinical benefit in confirmatory trial(s).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
- Thrombocytopenia: Monitor platelet counts throughout treatment.
Manage with dose interruption and/or reduction and supportive
care.
- Neutropenia: Monitor neutrophil counts throughout treatment.
Manage with dose interruption and/or reduction and granulocyte
colony–stimulating factors.
- Gastrointestinal Toxicity: Nausea, vomiting, diarrhea,
anorexia, and weight loss may occur. Provide antiemetic
prophylaxis. Manage with dose interruption and/or reduction,
antiemetics, and supportive care.
- Hyponatremia: Monitor serum sodium levels throughout treatment.
Correct for concurrent hyperglycemia and high serum paraprotein
levels. Manage with dose interruption, reduction, or
discontinuation, and supportive care.
- Serious Infection: Monitor for infection and treat
promptly.
- Neurological Toxicity: Advise patients to refrain from driving
and engaging in hazardous occupations or activities until
neurological toxicity resolves. Optimize hydration status and
concomitant medications to avoid dizziness or mental status
changes.
- Embryo–Fetal Toxicity: Can cause fetal harm. Advise females of
reproductive potential and males with a female partner of
reproductive potential, of the potential risk to a fetus and use of
effective contraception.
- Cataract: Cataracts may develop or progress. Treatment of
cataracts usually requires surgical removal of the cataract.
Adverse Reactions
- The most common adverse reactions (≥20%) in patients with
multiple myeloma who receive XVd are fatigue, nausea, decreased
appetite, diarrhea, peripheral neuropathy, upper respiratory tract
infection, decreased weight, cataract and vomiting. Grade 3–4
laboratory abnormalities (≥10%) are thrombocytopenia, lymphopenia,
hypophosphatemia, anemia, hyponatremia and neutropenia. In the
BOSTON trial, fatal adverse
reactions occurred in 6% of patients within 30 days of last
treatment. Serious adverse reactions occurred in 52% of patients.
Treatment discontinuation rate due to adverse reactions was
19%.
- The most common adverse reactions (≥20%) in patients with
multiple myeloma who receive Xd are thrombocytopenia, fatigue,
nausea, anemia, decreased appetite, decreased weight, diarrhea,
vomiting, hyponatremia, neutropenia, leukopenia, constipation,
dyspnea and upper respiratory tract infection. In the STORM trial,
fatal adverse reactions occurred in 9% of patients. Serious adverse
reactions occurred in 58% of patients. Treatment discontinuation
rate due to adverse reactions was 27%.
- The most common adverse reactions (incidence ≥20%) in patients
with DLBCL, excluding laboratory abnormalities, are fatigue,
nausea, diarrhea, appetite decrease, weight decrease, constipation,
vomiting, and pyrexia. Grade 3–4 laboratory abnormalities (≥15%)
are thrombocytopenia, lymphopenia, neutropenia, anemia, and
hyponatremia. In the SADAL trial, fatal adverse reactions occurred
in 3.7% of patients within 30 days, and 5% of patients within 60
days of last treatment; the most frequent fatal adverse reactions
was infection (4.5% of patients). Serious adverse reactions
occurred in 46% of patients; the most frequent serious adverse
reaction was infection (21% of patients). Discontinuation due to
adverse reactions occurred in 17% of patients.
Use In Specific Populations
Lactation: Advise not to
breastfeed.
For additional product information, including full prescribing
information,
please visit www.XPOVIO.com.
To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm
Therapeutics Inc. at 1–888–209–9326 or FDA at 1–800–FDA–1088 or
www.fda.gov/medwatch.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company pioneering novel cancer
therapies. Since its founding, Karyopharm has been an industry
leader in oral Selective Inhibitor of Nuclear Export (SINE)
compound technology, which was developed to address a fundamental
mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral
exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in
the U.S. and marketed by the Company in three oncology indications
and has received regulatory approvals in various indications in a
growing number of ex-U.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline
targeting multiple high unmet need cancer indications, including in
multiple myeloma, endometrial cancer, myelodysplastic neoplasms and
myelofibrosis. For more information about our people, science and
pipeline, please visit www.karyopharm.com, and follow us on Twitter
at @Karyopharm and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Such forward-looking statements include those regarding
Karyopharm's guidance on its 2023 total revenue, 2023 U.S. net
product revenue and 2023 non-GAAP R&D and SG&A expenses;
Karyopharm's expected cash runway; expectations with respect
to commercialization efforts; the ability of selinexor or eltanexor
to treat patients with multiple myeloma, endometrial cancer,
myelofibrosis, diffuse large B-cell lymphoma, myelodysplastic
neoplasms and other diseases; and expectations with respect
to the clinical development plans and potential regulatory
submissions of selinexor and eltanexor. Such statements are subject
to numerous important factors, risks and uncertainties, many of
which are beyond Karyopharm's control, that may cause actual events
or results to differ materially from Karyopharm's current
expectations. For example, there can be no guarantee that
Karyopharm will successfully commercialize XPOVIO or that any of
Karyopharm's drug candidates, including selinexor and eltanexor,
will successfully complete necessary clinical development phases or
that development of any of Karyopharm's drug candidates will
continue. Further, there can be no guarantee that any positive
developments in the development or commercialization of
Karyopharm's drug candidate portfolio will result in stock price
appreciation. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
factors, including the following: the adoption of XPOVIO in the
commercial marketplace, the timing and costs involved in
commercializing XPOVIO or any of Karyopharm's drug candidates that
receive regulatory approval; the ability to obtain and retain
regulatory approval of XPOVIO or any of Karyopharm's drug
candidates that receive regulatory approval; Karyopharm's results
of clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. Food and Drug Administration and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies, including with respect to the need for
additional clinical studies; the ability of Karyopharm or its third
party collaborators or successors in interest to fully perform
their respective obligations under the applicable agreement and the
potential future financial implications of such agreement;
Karyopharm's ability to enroll patients in its clinical trials;
unplanned cash requirements and expenditures; development or
regulatory approval of drug candidates by Karyopharm's competitors
for products or product candidates in which Karyopharm is currently
commercializing or developing; the direct or indirect impact of the
COVID-19 pandemic or any future pandemic on Karyopharm's business,
results of operations and financial condition; and Karyopharm's
ability to obtain, maintain and enforce patent and other
intellectual property protection for any of its products or product
candidates. These and other risks are described under the
caption "Risk Factors" in Karyopharm's Quarterly Report on Form
10-Q for the quarter ended June 30,
2023, which was filed with the Securities and Exchange
Commission (SEC) on August 2, 2023,
and in other filings that Karyopharm may make with the SEC in the
future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and, except as required
by law, Karyopharm expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm
Therapeutics Inc. Any other trademarks referred to in this release
are the property of their respective owners.
References:
1 For SVR 35: Events defined as less than or
equal to 35% spleen volume reduction from baseline and more than
25% increase in spleen volume from Nadir, assessed
radiographically. For TSS50: Events defined as a total symptom
score that is equal to or exceeds the baseline value. As of
August 1, 2023 data cut off.
2 Four multiple myeloma foundations provide financial
support to Medicare patients with multiple myeloma
3 Based on Komodo claims data analysis, accessed
in September 2023
KARYOPHARM
THERAPEUTICS INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited); (in
thousands, except per share amounts)
|
|
|
|
|
|
Three Months
Ended
September 30,
|
|
|
Nine Months
Ended
September 30,
|
|
|
|
2023
|
|
|
2022
|
|
|
2023
|
|
|
2022
|
|
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
Product revenue,
net
|
|
$
|
30,207
|
|
|
$
|
32,009
|
|
|
$
|
86,955
|
|
|
$
|
89,319
|
|
License and other
revenue
|
|
|
5,802
|
|
|
|
4,136
|
|
|
|
25,331
|
|
|
|
34,175
|
|
Total
revenue
|
|
|
36,009
|
|
|
|
36,145
|
|
|
|
112,286
|
|
|
|
123,494
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
|
|
911
|
|
|
|
980
|
|
|
|
3,456
|
|
|
|
3,345
|
|
Research and
development
|
|
|
35,553
|
|
|
|
31,359
|
|
|
|
99,369
|
|
|
|
117,730
|
|
Selling, general and
administrative
|
|
|
30,805
|
|
|
|
34,645
|
|
|
|
101,193
|
|
|
|
110,752
|
|
Total operating
expenses
|
|
|
67,269
|
|
|
|
66,984
|
|
|
|
204,018
|
|
|
|
231,827
|
|
Loss from
operations
|
|
|
(31,260)
|
|
|
|
(30,839)
|
|
|
|
(91,732)
|
|
|
|
(108,333)
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
income
|
|
|
2,750
|
|
|
|
658
|
|
|
|
8,423
|
|
|
|
1,025
|
|
Interest
expense
|
|
|
(6,073)
|
|
|
|
(6,114)
|
|
|
|
(17,615)
|
|
|
|
(19,111)
|
|
Other income
(expense), net
|
|
|
89
|
|
|
|
16
|
|
|
|
(145)
|
|
|
|
(70)
|
|
Total other expense,
net
|
|
|
(3,234)
|
|
|
|
(5,440)
|
|
|
|
(9,337)
|
|
|
|
(18,156)
|
|
Loss before income
taxes
|
|
|
(34,494)
|
|
|
|
(36,279)
|
|
|
|
(101,069)
|
|
|
|
(126,489)
|
|
Income tax
provision
|
|
|
(12)
|
|
|
|
(45)
|
|
|
|
(193)
|
|
|
|
(296)
|
|
Net loss
|
|
$
|
(34,506)
|
|
|
$
|
(36,324)
|
|
|
$
|
(101,262)
|
|
|
$
|
(126,785)
|
|
Net loss per
share—basic and diluted
|
|
$
|
(0.30)
|
|
|
$
|
(0.45)
|
|
|
$
|
(0.89)
|
|
|
$
|
(1.60)
|
|
Weighted-average number
of common shares outstanding used in net loss per share—basic and
diluted
|
|
|
114,401
|
|
|
|
80,210
|
|
|
|
114,033
|
|
|
|
79,153
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
KARYOPHARM
THERAPEUTICS INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(unaudited); (in
thousands)
|
|
|
|
|
September 30,
2023
|
|
|
December 31,
2022
|
|
Assets
|
|
|
|
|
|
Cash, cash equivalents
and investments
|
$
|
208,315
|
|
|
$
|
277,967
|
|
Restricted
cash
|
|
926
|
|
|
|
1,697
|
|
Accounts
receivable
|
|
37,923
|
|
|
|
47,086
|
|
Other assets
|
|
22,796
|
|
|
|
31,422
|
|
Total
assets
|
$
|
269,960
|
|
|
$
|
358,172
|
|
Liabilities and
stockholders' deficit
|
|
|
|
|
|
Convertible senior
notes
|
$
|
170,702
|
|
|
$
|
170,105
|
|
Deferred royalty
obligation
|
|
132,479
|
|
|
|
132,718
|
|
Other
liabilities
|
|
67,175
|
|
|
|
72,005
|
|
Total
liabilities
|
|
370,356
|
|
|
|
374,828
|
|
Total stockholders'
deficit
|
|
(100,396)
|
|
|
|
(16,656)
|
|
Total liabilities and
stockholders' deficit; 114,523 and 113,213 shares issued and
outstanding
at September 30, 2023
and December 31, 2022, respectively
|
$
|
269,960
|
|
|
$
|
358,172
|
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-reports-third-quarter-2023-financial-results-and-highlights-recent-company-progress-301975084.html
SOURCE Karyopharm Therapeutics Inc.